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Abstract (221 words) 
The NADPH oxidases are important transmembrane proteins producing reactive oxygen species 
(ROS). Within the Nox family, different modes of activation can be discriminated. Nox1-3 are 
dependent on different cytosolic subunits, Nox4 seems to be constitutively active and Nox5 is directly 
activated by calcium. With the exception of Nox5, all Nox family members are thought to depend on 
the small transmembrane protein p22phox. With the discovery of the CRISPR/Cas9-system, a tool to 
alter genomic DNA sequences has become available. So far, this method has not been widely used in 
the redox community. On such basis, we decided to study the requirement of p22phox in the Nox 
complex using CRISPR/Cas9-mediated knockout. Knockout of the gene of p22phox, CYBA, led to an 
ablation of activity of Nox4 and Nox1 but not of Nox5. Production of hydrogen peroxide or 
superoxide after knockout could be rescued with either human or rat p22phox, but not with the 
DUOX-maturation factors DUOXA1/A2. Furthermore, different mutations of p22phox were studied 
regarding the influence on Nox4-dependent H2O2 production. P22phox Q130* and Y121H affected
 
maturation and activity of Nox4. Hence, Nox5-dependent O
•-
 production is independent of p22phox, 
but native p22phox is needed for maturation of Nox4 and production of H2O2.  
 
Keywords 
NADPH oxidase, CYBA/p22phox, CRISPR/Cas9 
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Introduction 
The Nox family of NADPH oxidases is an important source of reactive oxygen species (ROS). 
Through ROS, Nox enzymes play diverse roles in cellular signaling, regulation of gene expression, 
cell differentiation and posttranslational protein modifications (Bedard und Krause 2007). In 
mammals, seven members are expressed and grouped according to their mode of activation. Nox1, 
Nox2 and Nox3 are activated by an assembly with specific cytosolic proteins, which translocate to the 
plasma membrane. On the other hand, Nox5 and DUOX1 as well as DUOX2 (Dual oxidase 1 and 2) 
are directly activated by calcium in a EF-hand motif dependent manner. To our current knowledge, 
Nox4, in contrast, is constitutively active and ROS production of the enzyme is mainly controlled by 
its expression level (Brandes et al. 2014). 
For DUOX1 or DUOX2, maturating factors are needed to achieve proper expression and activity. The 
small transmembrane protein p22phox/CYBA (Cytochrome B-245 Alpha Chain), was described to be 
essential for Nox1, Nox2 and Nox3 maturation, stabilization and activation (Zhu et al. 2006; Miyano 
und Sumimoto 2014; Nakano et al. 2007; Ambasta et al. 2004). P22phox has been found to interact 
with Nox4, indicating importance for Nox4 activity and localization (Ambasta et al. 2004; Martyn et 
al. 2006; Löhneysen et al. 2010). The exact site where p22phox interacts and activates Nox4 appears 
non-canocial with respect to Nox1, Nox2 or Nox3 (Löhneysen et al. 2008; Zhu et al. 2006). P22phox 
consists of two (or four) predicted transmembrane domains and an extended C-Terminus with a prolin-
rich region, which is required for the assembly with p47phox or NoxO1 to membrane-bound Nox1, 
Nox2 and Nox3 (Zhu et al. 2006; Brandes et al. 2014). This feature is dispensable for Nox4 indicating 
a different role for the p22phox-Nox4 activation (Löhneysen et al. 2008; Kawahara et al. 2005). 
Mutations in p22phox are associated with a loss of function leading to severe immunodeficiency 
called chronic granulomatous disease (CGD), with inability to clear some pathogens and subsequent 
life threatening infections (Bu-Ghanim et al. 1990; Dinauer et al. 1990).  
Further analysis of the structural and functional role of p22phox are necessary not just for 
understanding the Nox2-dependent pathogen defense, but also for the analysis of Nox4, as a protective 
cardiovascular enzyme.  
In the kidney, the endothelium and fibroblasts, Nox4 is the predominantly expressed Nox homologue 
(Ago et al. 2005; Clempus et al. 2007; Geiszt et al. 2000). Nox4 is fundamentally different to the other 
Nox enzymes and exhibits a different dependency on p22phox. Approaches to study p22phox-Nox4 
interaction like the p22phox mutant mouse nmf333 could only partially reveal the mechanisms 
underlying the relevant protein interaction (Nakano et al. 2008; Löhneysen et al. 2008). There is, 
however, no doubt that p22phox is important for Nox4 and changing the expression of this 
ubiquitously expressed protein alters H2O2 formation of most cells overexpressing Nox4 (Kawahara et 
al. 2005; Ambasta et al. 2004; Rezende et al. 2016). In previous work, Löhneysen et al. inserted 
mutations in p22phox which reduced Nox4-dependent H2O2 formation. A dual tryptophan motif in the 
N-terminal amino acids (aa) 6–11 was found necessary for Nox4 activity and localization. P22phox 
mutants of the first five -but not ten- aa did not impact on activity and are thus tolerated as well as 
deletion of aa after residue 130, which are involved in binding of p47phox or NoxO1 and activation of 
Nox1-3. In line with this, p22phox mutations in the C-terminal prolin-rich region (P156Q-P160Q) are 
tolerated for Nox4-derived H2O2 formation (Löhneysen et al. 2008; Kawahara et al. 2005). Point 
mutations in the putative membrane spanning domain are less well tolerated, e.g. non-conservative 
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exchange of arginine 90 (R90Q) abolished Nox4-dependent H2O2 production (Löhneysen et al. 2008; 
Roos et al. 1996).  
Given that protein abundance of p22phox is largely controlled by posttranscriptional mechanisms and 
that a few studies on complete knockout of p22phox have been performed so far, we set out to study 
the requirement of p22phox in the Nox complex using Clustered regulatory interspaced short 
palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated knockout. 
CRISPR/Cas9-mediated genome editing offers a fast and easy way to manipulate genomes in cell 
culture requiring just a 20-nucleotide targeting sequence, called guide RNA (gRNA). In one variant of 
RNA-guided Cas9 nuclease, the BbsI enzyme-mediated knockout strategy, a pair of gRNAs have been 
successfully used to mediate microdeletions e. g. in the Homeobox protein EMX1 (Ran et al. 2013).  
The p22phox
 
gene (CYBA) is located on the long arm of chromosome 16 and consists of six exons 
with a total length of approx. 8500 nucleotides (Dinauer et al. 1990). As the first exon is found in all 
predicted variants of p22phox, gRNAs targeting or flanking the exon 1 were chosen for 
microdeletions. In this study CRISPR/Cas9-mediated p22phox HEK (human embryonic kidney cells) 
knockout cell lines were used to study the role of endogenous p22phox on the expression, maturation 
and activity of Nox4, but also Nox1 and Nox5. Moreover, truncated and modified p22phox variants 
with essential N-terminal and membrane domain mutations were analyzed in a constitutive and 
inducible Nox4-overexpressing and p22phox-deficient cellular system.  
Materials and Methods 
Mutagenesis of p22phox
  
The QuikChange II XL Site-Directed Mutagenesis Kit (#200521, Agilent) was used to mutate 
p22phox. Primers were designed with the web-based QuikChange Primer Design Program. Briefly, 
the plasmid coding for human p22phox
 
(kindly provided by Thomas L. Leto, NIH) was used for 
mutant strand synthesis reaction with PfuUltra HF DNA polymerase (2.5 U/µl) according to the kit, 
followed by a DpnI (10 U/µl) digestion of the original strand. The mutated plasmid was transformed 
into XL10-Gold Ultracompetent cells, the generated plasmid was purified with the GenJet Plasmid 
Miniprep Kit (K0503, Thermo Scientific). Mutations were verified by sequencing. The following 
primers were used for the introduction of single amino acid mutation: CYBA A91stop 5’-GAG AGC 
AGG AGA TGC AGG ACC TAC CGA ACA TAG TAA TTC CTG G-3’ and 5’-CCA GGA ATT 
ACT ATG TTC GGT AGG TCC TGC ATC TCC TGC TCT C-3’; CYBA E5A 5’-CCA CAT GGC 
CCA CGC GAT CTG CCC CAT-3’ and 5’ATG GGG CAG ATC GCG TGG GCC ATG TGG-3; 
CYBA E12A 5’CCA GCG CCT GCG CGT TGG CCC AC-3’2 and 5’-GTG GGC CAA CGC GCA 
GGC GCT GG-3’; CYBA G110stop 5’-CTG CTG GCC ACC ATC CTT TAG ACC GCC TGC-3’and 
5’-GCA GGC GGT CTA AAG GAT GGT GGC CAG CAG-3’; CYBA I110C 5’-CCG CCA GTA 
GGT AGC AGC CGC TCG CAA TGG-3’ and 5’-CCA TTG CGA GCG GCT GCT ACC TAC TGG 
CGG-3; CYBA Q130stop 5’-TGG GCG TCC ACT ACT CGC CAC GCA C-3’ and 5’-GTG CGT 
GGC GAG TAG TGG ACG CCC A-3’; CYBA R90Q 5’-GCC CTT TAC CAG GAA TTA CTA TGT 
TGA GGC CGT CCT GCA T-3’and 5’-ATG CAG GAC GGC CTC AAC ATA GTA ATT CCT GGT 
AAA GGG C-3’; CYBA R90stop 5’-ATG CAG GAC GGC CTA AAC ATA GTA ATT CCT GGT 
AAA GGG C-3; CYBA r90stop 5’-GCC CTT TAC CAG GAA TTA CTA TGT TTA GGC CGT CCT 
GCA T-3; CYBA Y121H 5’-CCG CCA GTA GGT GGA TGC CGC TCG C-3’ and 5’-GCG AGC 
GGC ATC CAC CTA CTG GCG G-3’ as well Nox5 T493K 5’-CAG GAG CAC TGC TGA TCT 
TGA AGG GGT GCC ACTC-3’ and 5’-GAG TGG CAC CCC TTC AAG ATC AGC AGT GCT CCT 
G-3’. 
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Cell culture 
Human embryonic kidney 293 cells (HEK293) cells were obtained from ATCC (Manassas, VA, USA) 
and cultured in Modified Eagle's Medium (MEM, Gibco) supplemented with fetal calf serum (FCS; 
8%), non-essential amino acids (0.1 mM), sodium pyruvate (1 mM) and gentamycin (50 μg/mL) in a 
humidified atmosphere (5% CO2, 37 °C). HEK293 cells expressing human Nox4 with a tetracycline-
inducible tet-on operator (Nox4-pDEST30) were kindly provided by K.-H. Krause (University of 
Geneva, Switzerland) (Serrander et al. 2007). Induction with 1 µg/mL tetracycline was performed for 
24 h in HEK medium. HEK293 cells stably expressing human Nox4 (Nox4-HEK293) were generated 
as described before using lentiviral transfection and selection (Helmcke et al. 2009). 
Transfection of Nox constructs 
Transient transfection of HEK293 cells was performed using Lipofectamine 2000 (#11668027, 
ThermoFisher) and 0.75 µg/mL plasmid DNA according to the manufacturer’s instructions. Cells were 
kept in culture for 48 h. DUOXA1 and DUOXA2 plasmids were kindly provided by H. Grasberger 
(University of Michigan Medical School, Michigan). 
Cloning of pHAGE2-NoxO1-NoxA1-Nox1 for transient overexpression 
To clone NoxO1, NoxA1 and Nox1 as lentiviral triple overexpression plasmid under control of the 
human EF1a promoter, in which NoxO1 and NoxA1 are divided by a 2A peptide (F2A) and NoxA1 
and Nox1 separated by an internal ribosome entry site (IRES), PCR amplifications of NoxO1, NoxA1 
and Nox1 were performed from pCMV6-NoxO1 (NM_172167, #RC214973, Origene), pCMV6-
NoxA1 (NM_001256067, #RC234211, Origene) and pCMV6-Nox1 (NM007052, #RC210426, 
Origene) Human cDNA ORF clones with the following primers: NoxO1 forward 5’-ATA GCG GCC 
GCC ATG GCA GGC CCC CGA TAC CCA GTT TCA GTG-3’ and NoxO1 reverse 5’-ATT TGC 
TTA GCC CCT GCT CCG TCG TGG GGT GCG GC-3’, NoxA1 forward 5’-ATT AGC TAG CAT 
GGC CTC TCT GGG GGA CCT GGT GCG-3’ and NoxA1 reverse 5’-ATT TGG ATC CTT AGG 
GCT GAT CTC CCT GCT GGG ATC GGG-3’ and Nox1 forward 5’-ATA TTA CAT ATG ATG 
GGA AAC TGG GTG GTT AAC CAC-3’ and Nox1 reverse 5’-ATT GAT TAG GAT CTA TCG 
ACT CAA AAA TTT TCT TTG TTG AAG TAG-3’. In parallel, a F2A region for placing between 
NoxO1 and NoxA1 was amplified with 5’-ATT TGC TAA GCA CGG GTT CGG GTG CGC CAG 
TAA AGC AGA C-3’ and 5’-ATT TGC TAG CTG GAC CTG GAT TTG ACT CTA CAT CAC-3’ 
from pHAGE2, which was a gift from G. Mostoslavsky (Boston University, MA, USA) (Somers et al. 
2010). PCR products were cut in the following way to achieve a specific order of integration into 
pHAGE2: NoxO1 (NotI/BlpI (#ER0591, #ER0091, ThermoFisher), F2A (BlpI/NheI (#ER0091, 
#ER0972, ThermoFisher), NoxA1 (NheI/BamHI (#ER0972, #ER0055, ThermoFisher) and Nox1 
(NdeI/BsaBI (#ER0581, #ER1711, ThermoFisher). In a first ligation reaction, pHAGE2 cut by 
BamHI/NotI (#ER0055, #ER0591, ThermoFisher) was used to be ligated with restricted NoxO1, F2A 
and NoxA1. This intermediate product was purified and further cut by NdeI/BsaBI (#ER0581, 
#ER1711, ThermoFisher) to be ligated in a second reaction with restricted Nox1. The final plasmid 
(pHAGE2-NoxO1-NoxA1-Nox1) was purified and sequenced.  
Cloning of pHAGE2-Nox5 for stable overexpression 
To clone pHAGE2-Nox5 for lentiviral overexpression under the control of the human EF1a promoter, 
Nox5 was amplified from pCMV6-Nox5 (NM_001184779) Human cDNA ORF Clone (#RC230471, 
Origene) with the following primers: 5’- ATT GCG GCC GCC ATG AAC ACA TCT GGA GAC 
CCA GCC CAG AC-3’ and 5’-ATT TGA TTA GGA TCT ATC GAC CTA GAA ATT CTC TTG 
GAA AAA TCT G-3’. pHAGE2 was a gift from Gustavo Mostoslavsky (Somers et al. 2010). . Nox5 
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PCR product and pHAGE2 were cut with NotI/BsaBI (#ER0591, #ER1711, ThermoFisher) followed 
by ligation. Plasmid was purified and sequenced.  
Lentiviral Transfection of HEK293 cells with pHAGE2-Nox5 
Vesicular stomatitis virus (VSV) pseudotyped lentivirus was produced by transfection of HEK293T 
cells with pHAGE2-Nox5 in combination with HGPM2, Tat1B, Rev1B and VSV-G, which were a gift 
from Bianling Liu. Viral supernatants were collected, concentrated and snap-frozen after four days. 
Transfection of 70% subconfluent HEK293 with Nox5 viral particles was performed for 12 days, 
followed by clonal expansion. 
CRISPR/Cas9 
The web interface of CRISPR design (http://crispr.mit.edu/) was used to develop gRNAs. Off-target 
activity was evaluated additionally with Blastn (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The 
pSpCas9(BB)-2A-Puro (PX459) v2.0 was a gift from Feng Zhang (Addgene plasmid # 62988) and 
used as cloning backbone. CRISPR/Cas9 was carried out similar as in Josipovic et al. 2016 and Ran et 
al. 2013. Briefly, phosphorylation and annealing was performed with the following oligonucleotides 
harboring a BbsI overhang: For (A) CYBA_1_Exon1  with 5’-CAC CGG CCG GGT TCG TGT CGC 
CAT G-3’ and 5’-AAA CCA TGG CGA CAC GAA CCC GGC C-3’, for (B) CYBA_2_Exon1 with 
5’-CAC CGG GAC GCC AGC GCC TGT TCG T-3’ and 5’-AAA CAC GAA CAG GCG CTG GCG 
TCC C-3’, for (C) CYBA_3_Exon1 with 5’-CAC CGG GCC ATG TGG GCC AAC GAA C-3’ and 
5’-AAA CGT TCG TTG GCC CAC ATG GCC C-3’, for (D) CYBA_1_Intron1 with 5’-CAC CGG 
TGC ACG TCA GGG ACG GTG G-3’ and 5’-AAA CCC ACC GTC CCT GAC GTG CAC C-3’, for 
(E) CYBA_2_Intron1 with 5’-CAC CGC GGG ACC TCG GGC TAC TTA C-3’ and 5’-AAA CGT 
AAG TAG CCC GAG GTC CCG C-3’, for (F) CYBA_3_Intron1 with 5’-CAC CGC CCA CCC TGT 
AAG TAG CCC G-3’ and 5’-AAA CCG GGC TAC TTA CAG GGT GGG C-3’ and for (G) 
CYBA_2_5’UTR with 5’-CAC CGC GGG GTT CGG CCG GGA GCG C-3’ and 5’-AAA CGC GCT 
CCC GGC CGA ACC CCG C-3’. Afterwards, BbsI (#FD1014, ThermoFisher) mediated digestion and 
T7 DNA ligase (#M0318L, NEB) directed ligation was performed followed by PlasmidSafe 
exonuclease treatment (#E3101K, Epicentre/Biozym) according to the manufacturers protocol. 
Plasmids were purified and sequenced. After transfection of the indicated combinations of 
pSpCas9(BB)-2A-Puro-gRNAs (Fig. 1B), positive cells were selected using puromycin (2 μg mL
−1
) 
for five days prior to clonal expansion. Empty pSpCas9(BB)-2A-Puro was used as negative control. 
Determination of H2O2 production by luminol/HRP assay 
ROS production was measured as described before (Rezende et al. 2016; Prior et al. 2016). As probe, 
luminol (100 µM, #123072, Sigma) catalyzed by horseradish peroxidase (HRP, 1 U/ml, #P6782, 
Sigma) or L012 (250 µM, #120-04891, Wako) was used and measured in a TriStar
2
 Multimode 
Reader (LB942, Berthold, Wildbad, Germany). 
Western Blot Analysis  
Triton-lysed samples were substituted with sample buffer (8.5% glycerin, 2% SDS, 6.25% TRIS/HCl 
pH 6.8, 20 mM DTT, 0.013% bromphenol blue) but not heat-denatured. As a reducing agent TCEP 
(tris(2-carboxyethyl)phosphine, Thermo Scientific) was used as described before (Schröder et al. 
2012). Protein amounts were determined by Bradford protein assay. Proteins were separated by SDS-
PAGE, substituted to Western analysis and detected by primary antibodies. Infra-red-fluorescent-
labelled secondary antibodies were used and visualized in the Odyssey system (Licor, Bad Homburg, 
Germany). Nox4 was detected by an anti-Nox4 antibody (1:2000) reported by Anilkumar et al. 
(Anilkumar et al. 2008). Primary antibodies against Nox1 (Mox1, #sc-5821, 1:500), Nox5 (#sc-67006, 
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1:500) and p22phox (#sc-20781, 1:500) were purchased from Santa Cruz, β-Actin (#A1978, 1:2000) 
was obtained from Sigma. 
RNA isolation and RT-qPCR  
RNA was isolated with the RNA Mini-Kit (#BS67.311, Bio&Sell) according to the manufacturer’s 
instructions. Random hexamer primers (#C1181, Promega) and SuperScript III Reverse Transcriptase 
(RT, #18080044 ThermoFisher) were used for reverse transcription. A non-RT control was used. 
CDNA was used for semi-quantitative real-time PCR using iQ™ SYBR® Green Supermix (#1708880, 
BioRad) in a Mx3000P qPCR cycler (Agilent Technologies). Relative mRNA expression was 
normalized to RNA Polymerase IIa (POLR2A) and analyzed by the delta–delta-Ct method. Results are 
shown as relative to the corresponding control. Primer sequences are summarized in Table 1. 
Statistical Analysis 
Values are mean ± SEM (standard error of mean) if not otherwise indicated. Statistical analysis was 
carried out using Prism 3.02. For multiple testing ANOVA followed by post hoc testing (Bonferroni's 
Multiple Comparison Test) was used. Unless otherwise indicated, n indicates the number of individual 
experiments. Densitometry was performed using the Odyssey-software (Image studio lite 5.0) and 
normalized to corresponding reference protein β-Actin. A p-value of less than 0.05 was considered 
statistically significant (*p<0.05; **p<0.01; ***p<0.001). 
Results 
CRISPR/Cas9-mediated knockout of CYBA/p22phox
 
 
To study the role of endogenous p22phox on Nox-dependent ROS formation, different guide RNAs 
(gRNAs) against the p22phox gene CYBA were designed (Fig. 1A, 1B). Seven different gRNAs were 
transfected into stable Nox4- (Fig. 1C; Nox4-HEK293) or tetracycline-inducible Nox4 HEK293 cells 
(Fig. 1D; tetNox4-HEK293) and CRISPR/Cas9-mediated knockout was validated by Western Blot. 
Whereas single gRNA usage resulted in p22phox protein reduction, most of the gRNA combinations 
displayed loss of p22phox in both HEK293 cell types (Fig. 1B, 1C, 1D). Complete loss of p22phox 
was achieved with a combination of three gRNAs (Fig. 1B&C; combination 17) or all seven gRNAs 
(Fig. 1B&C; combination 18). For the subsequent experiments, the most effective combinations were 
used with cells targeted with two or three gRNAs with the combinations 1, 4, 7, 8, 10 and 17.  
Knockout of endogenous p22phox reduces Nox4-dependent H2O2 production, but not Nox4 
expression 
To test the influence of CRISPR/Cas9-mediated p22phox knockout on Nox4-dependent ROS 
production, Nox4 constitutively overexpressing (Fig. 2 left) and induced tetNox4-overexpressing 
HEK293 cells (Fig. 2 right, tetracycline 1 µg/mL, 24 h) were studied in the Luminol/HRP assay. 
P22phox and Nox4 mRNA as well as protein expression were studied in the cells subjected to ROS 
measurements (Fig. 2A, 2B, 2E, 2F, 2G, 2H). Deletion of p22phox resulted in a strong reduction of 
ROS production, and the extent of the effect correlated with the p22phox mRNA and protein 
expression but not with Nox4 mRNA or protein expression. Interestingly, the inhibitory effect on ROS 
formation appeared more prominent in the constitutively overexpressing than in the tet-inducible cells 
(Fig. 2C&D). Although deletion of p22phox lowered ROS formation, it certainly did not abolish it. 
This effect could potentially be a consequence of insufficient transfection efficiency. 
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Knockout of endogenous p22phox completely abolishes Nox4-dependent H2O2 production 
To generate defined p22phox-deficient cells, Nox4- and tetNox4-HEK293 cells, harboring the most 
effectively reduced p22phox
 
expression (gRNA combination 1 and combination 10), were clonally 
expanded. Multiple clones were tested on p22phox expression and H2O2 production and three of these 
were chosen for the subsequent studies. The three tested clones of either constitutive expressing Nox4-
HEK293 cells (Fig. 3A) or tetracycline-induced tetNox4-HEK293 cells (Fig. 3B) displayed a complete 
loss of H2O2 production measured by luminol/HRP assay, in comparison to the empty vector control. 
Despite some unspecific bands in the Western blot, p22phox could not be detected in all three clonally 
expanded CRISPR/Cas9-knockout cell lines (C1 or C10). As the starting population of the clonal 
expansion with variable regarding Nox4 expression, Nox4 expression level also varied in the different 
p22phox-knockout cell lines. Hence, the H2O2 production is not dependent on Nox4 expression as 
seen in the Western blot, but on p22phox expression only. The clones C1-1 and C10-1 were used for 
all following experiments. 
ROS production after p22phox
 
knockout can be restored with p22phox, but not with DUOXA1 or 
DUOXA2 
The clonally expanded p22phox knockout cells are an ideal tool for reconstitution experiments.. 
Transfection of the cells with plasmids coding for human p22phox (hp22) as well as rat p22phox 
(rp22) restored the ROS production in Nox4-HEK293 cells as well as tetNox4-HEK293 cells (Fig. 
4A&B). To test the hypothesis that DUOX1/2 maturation factors may substitute p22phox, DUOXA1 
(DA1) and/or DUOXA2 (DA2) were also transfected. Importantly, the DUOX maturation factors did 
not affect ROS formation (Fig. 4A&B) and therefore cannot substitute p22phox.  
p22phox
 
is required for Nox1-, but not Nox5-dependent O2
-
 production 
To test whether other Nox isoforms are also influenced by the knockout of endogenous p22phox, 
p22phox deficient cells were transiently transfected with either a NoxO1-NoxA1-Nox1 expressing 
plasmid or with a Nox5 plasmid. Despite knockout of p22phox, Nox5 transfected cells exhibited PMA 
(phorbol 12-myristate 13-acetate; 100 nM)-stimulated ROS production as detected by L012 
chemiluminescence (Fig. 5A, CYBA KO1&2). A similar effect was observed in stably transduced 
Nox5-HEK293 cells subjected to CRISPR/Cas9 p22phox knockout with different combinations of 
gRNAs (1, 4, 7, 8, 10, 17) (Fig. 5B). In contrast, p22phox-deficiency completely abolished Nox1-
dependent O
•-
 production (Fig. 5C, CYBA KO1&2), whereas Nox1 expression was not changed (Fig. 
5C). Thus, Nox5 but not Nox1-mediated ROS is independent of p22phox in contrast to Nox1 or Nox4. 
Analysis of p22phox mutants and their effect on Nox4-dependent ROS production 
To gain insights into the function of p22phox in Nox4-dependent ROS production, mutations were 
studied. First, c-terminal truncations were analyzed (Fig. 6A&B). Truncation beyond Q130 resulted in 
a complete loss of enzyme activity, whereas the protein truncated at Q130 still showed some ROS 
activity. Interestingly, this effect was more pronounced in the tetNox4-HEK293 cells as compared to 
the Nox4 stably expressing cells, potentially suggesting that the dynamic of Nox4 protein formation is 
relevant for this mutation. Importantly, these observations are in stark contrast to a previous 
publication, which reported that a p22phox-Q130 truncation was fully active (Löhneysen et al. 2008). 
Truncations at aa90, aa91 or aa110 were indispensable for Nox4 activity (Fig. 6A&B). 
As several CGD patients carry the p22phox missense mutation R90, we also tested a R90Q mutant 
(Roos et al. 1996) on its effect on Nox4 (Fig. 6C&D). The mutation not only leads to a loss of Nox4-
dependent H2O2 formation, it also exhibited reduced p22phox protein expression. Mutations of 
negatively charged amino acids at the beginning of the N-terminus (E5A, E12A) or aliphatic amino 
acid close to the predicted Nox1/2-p22phox interaction site (I120C) had no influence on Nox4-
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dependent ROS production (Fig. 6C&D). Interestingly, the Y121H mutation, previously described by 
Banfi et al. in Cyba-deficient mice (Nakano et al. 2008) only resulted in ROS formation in the 
tetracycline-induced Nox4-HEK293 cells, whereas in the constitutive Nox4-HEK293 cells only a 
minimal effect on ROS production was achieved. None of the mutants had a dominant negative effect. 
I.e. transfection of the p22phox mutants into HEK cells overexpressing Nox4 but expressing 
endogenous p22phox had only a very minor effect on ROS formation (Sup. Fig. 1). 
These results highlight the importance of R90, the transmembrane region aa90-130 and also indicate 
importance for Y121 and aa130-195 for Nox4 activity. 
Discussion 
In this study using CRISPR/Cas9-mediated knockout cell lines we demonstrate that p22phox deficit 
completely abolishes Nox1 and Nox4 but not Nox5-dependent ROS production. In contrast, 
expression levels of these Nox enzymes were independent of p22phox. The effect of the knockouts 
could be rescued with either human or rat p22phox, but not with the DUOX-maturation factors 
DUOXA1/A2. Truncation of p22phox till the amino acid 130 was without a functional consequence, 
while further truncation leads to a reduced function of the protein. Exchange of conserved negatively 
charged amino acids at the very N-terminus did not impact on Nox4-dependent ROS formation, 
whereas the R90Q mutant was not able to produce significant amounts of ROS. Surprisingly, the C-
Terminus of p22phox was just dispensable in tetracycline-induced HEK293 cells. In constitutive 
Nox4-expressing cells, truncation of p22phox with Q130stop could not rescue the p22phox knockout. 
The same was observed for Y121H p22phox, which just restored the ROS producing capacity of 
tetracycline-induced Nox4. This might suggest that these parts of the protein are important during the 
de novo formation of the Nox-p22phox complex.  
The functional interaction of the catalytically active Nox enzyme with p22phox on ROS formation is 
in line with previous work employing p22phox shRNA, siRNA or overexpression of Nox and 
p22phox (Kawahara et al. 2005; Löhneysen et al. 2008; Martyn et al. 2006). The rescue with either 
truncated Q130stop or Y121H p22phox was described for co-overexpression of p22phox and Nox4 
(Löhneysen et al. 2008). This could be confirmed with the tetracycline-inducible Nox4 expression 24 
h after the transfection with p22phox. Therefore, Nox4 is transcribed, translated and matured after the 
p22phox Q130stop or Y121H p22phox overexpression. In the constitutively expressing Nox4-
HEK293 cells, Nox4 is already expressed in the absence of p22phox. Our data therefore suggest an 
involvement of the C-terminal part of p22phox in the maturation of the p22phox-Nox4 interaction. 
Since Nox4 is not dependent on cytosolic subunits to form a functional Nox complex the role of 
p22phox is rather stabilization then activation (Serrander et al. 2007; Peshavariya et al. 2009; Desai et 
al. 2014). Nox1, Nox2 and Nox3 maturation and glycosylation have also been described to be 
p22phox-dependent, but these isoforms are furthermore dependent on the direct activation by p22phox 
by the prolin-rich region in the C-terminus of p22phox (Nakano et al. 2007; Miyano und Sumimoto 
2014). This region is dispensable for Nox4 activation as shown in the tetNox4-HEKs and co-
expression studies by others (Kawahara et al. 2005; Löhneysen et al. 2008).  
Zhu et al. described the dependence of Nox2 maturation on amino acids 6-142 (Zhu et al. 2006). 
Therefore we propose that also Nox4 maturation is dependent on the amino acids 6-130. In line with 
this, deletion of the first five amino acids, but not 11 amino acids, is tolerated by Nox4 as shown in a 
previous study (Löhneysen et al. 2008). Controversially, a peptide targeting the amino acids 6-11 
(WAMWAN) did not inhibit Nox4-derived ROS production (Csányi und Pagano 2013). Furthermore, 
it was also reported that the D-Loop of Nox4 is responsible for the Nox4-p22phox activation 
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suggesting an ionic interaction (Löhneysen et al. 2010). We tested if substitution of inter-species 
conserved negatively charged glutamic acid in the N-terminal region influence Nox4 activity. Neither 
E5A nor E12A reduced Nox4 activity in p22phox-deficient HEK293 cells. Further studies on the 
structural relevance of the N-Terminus for Nox4 maturation and activity are thus needed to understand 
the mechanism underlying p22phox function.  
For Nox1-3 a 1:1 p22phox heterocomplex formation is proposed for the activation and assembly of 
functional Nox complexes at the plasma membrane, whereas Nox5 forms homooligomers and does not 
require p22phox (Kawahara et al. 2011). In this and in other studies Nox4 overexpression yielded high 
ROS production with endogenous p22phox (Kawahara et al. 2005; Helmcke et al. 2009; Ambasta et 
al. 2004; Rezende et al. 2016). In HEK293 cells, co-overexpression of p22phox or its mutants did not 
further increase ROS production. This effect, however, is cell-type specific and in other cells, like 
COS-7 or PLB cells, basal p22phox mRNA expression might be insufficient to provide sufficient 
protein to the Nox enzyme. Maturation of Nox enzymes in general is a complex process and other 
proteins, like protein disulfide isomerase (Janiszewski et al. 2005) or Calnexin (Prior et al. 2016) also 
contribute to the process. Further studies are needed to understand the process in detail to dissect the 
precise mode of p22phox – Nox interaction. 
In summary, we used CRISPR/Cas9 to reliably and rapidly alter genomic CYBA DNA sequences and 
induced a knockout of p22phox in two Nox4-overexpressing cell lines. We demonstrated that rapid 
deletion of p22phox is possible and that the activity of Nox1 and Nox4 but not Nox5 exclusively 
depends on p22phox.  
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Table 1: RT-qPCR Primer 
Gen 
 
Sequence (5’-3’) 
h POLR2A  
forward GCACCACGTCCAATGACAT 
reverse GTGCGGCTGCTTCCATAA 
h Nox4 
forward TCCGGAGCAATAAGCCAGTC 
reverse CCATTCGGATTTCCATGACAT 
h CYBA 
forward TACTATGTTCGGGCCGTCCT 
reverse CACAGCCGCCAGTAGGTA 
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